title: Haemolytic uraemic syndrome after gemcitabine treatment for pancreatic carcinoma.
authors.forename: M
authors.initials: M
authors.lastname: Choi
authors.forename: A
authors.initials: A
authors.lastname: Woywodt
authors.forename: U
authors.initials: U
authors.lastname: Göbel
authors.forename: W
authors.initials: W
authors.lastname: Schneider
authors.forename: R
authors.initials: R
authors.lastname: Kettritz
mesh_terms: D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects*; D003841:Deoxycytidine / Q000009:adverse effects / Q000031:analogs & derivatives*; D006463:Hemolytic-Uremic Syndrome / Q000139:chemically induced*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D000093542:Gemcitabine
chemical_list: D000964:Antimetabolites, Antineoplastic; D003841:Deoxycytidine; D000093542:Gemcitabine